Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection

Nanoscale. 2021 Apr 7;13(13):6410-6416. doi: 10.1039/d1nr00309g. Epub 2021 Mar 25.

Abstract

The control of COVID-19 across the world requires the formation of a range of interventions including vaccines to elicit an immune response and immunomodulatory or antiviral therapeutics. Here, we demonstrate the nanoparticle formulation of a highly insoluble drug compound, niclosamide, with known anti SARS-CoV-2 activity as a cheap and scalable long-acting injectable antiviral candidate.

MeSH terms

  • Antiviral Agents* / administration & dosage
  • Antiviral Agents* / pharmacology
  • COVID-19 / drug therapy*
  • Humans
  • Injections, Intramuscular
  • Nanoparticles
  • Niclosamide* / administration & dosage
  • Niclosamide* / pharmacology
  • SARS-CoV-2 / drug effects*

Substances

  • Antiviral Agents
  • Niclosamide